Drug Profile
Tavilermide
Alternative Names: MIM-D3Latest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator Mimetogen Pharmaceuticals
- Class Amides; Aza compounds; Cyclic ethers; Eye disorder therapies; Neuroprotectants; Nitrobenzoates; Small molecules
- Mechanism of Action TrkA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
- No development reported Glaucoma
Most Recent Events
- 28 Jun 2023 Mimetogen Pharmaceuticals initiates a phase III trial for Dry eyes (Ophthalmic) in USA (NCT05848128)
- 11 May 2023 Mimetogen Pharmaceuticals plans a phase III trial for dry eyes (Opthalmic, Liquid) in May 2023 (NCT05848128)
- 11 Jun 2020 Mimetogen Pharmaceuticals completes a phase III trial for Dry eyes in USA (Ophthalmic) (NCT03925727)